ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mezigdomide

Also written as “CC-92480”, “Mezigdomide” and “Cohort B1 & B2: KTX-1001+Mezigdomide”.

Its studies are mostly in Multiple Myeloma · Kidney Failure, Chronic, led by 2 companies.

Drug pageMezigdomide: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 25, 202212 company-led studies, 4 open or runningNext primary completion: Jan 10, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb113 open or runningphase 3since Aug 25, 2022Dec 1, 2017Jan 10, 2027phase 3 · NCT05519085
K36 Therapeuticsits history only11 open or runningphase 1since Dec 1, 2022Dec 1, 2022Dec 31, 2027phase 1 · NCT05651932
  • Named in Bristol-Myers Squibb’s own pipeline as mezigdomide, phase 4, as of Oct 29, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2017First study: phase 2 study in Multiple MyelomaFirst studyNCT03374085 · 200 enrolled · United States, Australia, Belgium and more
  2. Dec 17, 2018Phase 1 study in Healthy VolunteerNCT03803644 · 56 enrolled · United States
  3. Dec 24, 2019Phase 1 study in Healthy VolunteerNCT04211545 · 24 enrolled · United States
  4. Sep 21, 2020Phase 1 study in Healthy VolunteersNCT04560738 · 8 enrolled · United States
  5. Apr 7, 2021Phase 1 study in Healthy VolunteersNCT04839809 · 40 enrolled · United States
  6. Jul 28, 2021Named mezigdomideINNProposed as its International Nonproprietary Name in WHO's List 125 · before, CC-92480
  7. May 20, 2022Phase 1 study in Healthy VolunteersNCT05389722 · 24 enrolled · United States
  8. Aug 25, 2022Phase 3 study in RecurrenceNCT05519085 · 810 planned · United States, Argentina, Australia and more
  9. Sep 21, 2022Phase 3 study in RecurrenceNCT05552976 · 606 enrolled · United States, Argentina, Australia and more
  10. Jan 23, 2023Phase 1 study in Hepatic ImpairmentNCT05707390 · 32 enrolled · United States
  11. Mar 12, 2024Phase 1 study in Renal InsufficiencyNCT06318676 · 26 enrolled · United States
  12. May 16, 2025Phase 2 study in Multiple MyelomaNCT06988488 · 62 planned · United States, Canada, China and more

Ahead

  1. Jan 10, 2027Primary completion: phase 3 study in RecurrenceNCT05519085
  2. May 31, 2027Primary completion: phase 2 study in Multiple MyelomaNCT06988488

TargetBeta

“A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and target…”NCIt, read by Claude

Other programs on CRBN

ProgramCompanyFurthest phaseStudies
LenalidomideruleBristol-Myers Squibbphase 4109
pomalidomideruleBristol-Myers Squibbphase 451
golcadomideBristol-Myers Squibbphase 311
Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506Bristol-Myers Squibbphase 11
HRS-3738Jiangsu HengRui Medicinephase 11

Studies

All 11 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06988488Multiple Myeloma · United States, Canada, China and more2RecruitingMay 31, 202762
NCT06318676Renal Insufficiency · United States1CompletedNov 15, 202426
NCT05707390Hepatic Impairment · United States1CompletedSep 13, 202332
NCT05552976Recurrence · United States, Argentina, Australia and more3Active, not recruitingSep 28, 2026606
NCT05519085Recurrence · United States, Argentina, Australia and more3RecruitingJan 10, 2027810
NCT05389722Healthy Volunteers · United States1CompletedNov 12, 202224
NCT04839809Healthy Volunteers · United States1CompletedOct 8, 202140
NCT04560738Healthy Volunteers · United States1CompletedMay 13, 20218
NCT04211545Healthy Volunteer · United States1CompletedDec 26, 201924
NCT03803644Healthy Volunteer · United States1CompletedMay 28, 201956
NCT03374085Multiple Myeloma · United States, Australia, Belgium and more2TerminatedAug 20, 2025200

How it is read

Names in the registry

  • “CC-92480”, 6 entries
  • “Mezigdomide”, 4 entries
  • “Cohort B1 & B2: KTX-1001+Mezigdomide”, 1 entry
  • “mezigdomide”, 1 entry
  • “[14C]-CC-92480”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.